Literature DB >> 18985363

Analysis of the IDH1 codon 132 mutation in brain tumors.

Jörg Balss1, Jochen Meyer, Wolf Mueller, Andrey Korshunov, Christian Hartmann, Andreas von Deimling.   

Abstract

A recent study reported on mutations in the active site of the isocitrate dehydrogenase (IDH1) gene in 12% of glioblastomas. All mutations detected resulted in an amino acid exchange in position 132. We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas. A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%). Primary glioblastomas and other entities were characterized by a low frequency or absence of mutations in amino acid position 132 of IDH1. The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985363     DOI: 10.1007/s00401-008-0455-2

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  392 in total

1.  Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.

Authors:  Xianyuan Song; R Andrew Allen; S Terence Dunn; Kar-Ming Fung; Peter Farmer; Shital Gandhi; Tulika Ranjan; Alexis Demopoulos; Marc Symons; Michael Schulder; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2011-09-17

Review 2.  MGMT promoter methylation in malignant gliomas.

Authors:  Markus J Riemenschneider; Monika E Hegi; Guido Reifenberger
Journal:  Target Oncol       Date:  2010-08-20       Impact factor: 4.493

3.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Emiko J Holmes; Tianni Zhou; Regina I Jakacki
Journal:  Childs Nerv Syst       Date:  2010-08-20       Impact factor: 1.475

4.  IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma.

Authors:  Ying Liu; Wenqing Jiang; Jing Liu; Shimin Zhao; Ji Xiong; Ying Mao; Yin Wang
Journal:  J Neurooncol       Date:  2012-07-08       Impact factor: 4.130

5.  Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.

Authors:  Shuyu Hao; Christopher S Hong; Jie Feng; Chunzhang Yang; Prashant Chittiboina; Junting Zhang; Zhengping Zhuang
Journal:  J Neurosurg       Date:  2015-10-16       Impact factor: 5.115

6.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.

Authors:  Wei Yan; Wei Zhang; Gan You; Junxia Zhang; Lei Han; Zhaoshi Bao; Yongzhi Wang; Yanwei Liu; Chuanlu Jiang; Chunsheng Kang; Yongping You; Tao Jiang
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

7.  Anaplastic PXA in adults: case series with clinicopathologic and molecular features.

Authors:  Yao Schmidt; B K Kleinschmidt-DeMasters; Dara L Aisner; Kevin O Lillehei; Denise Damek
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

Review 8.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors:  Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

Review 9.  Molecular markers in pediatric neuro-oncology.

Authors:  Koichi Ichimura; Ryo Nishikawa; Masao Matsutani
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

10.  Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.

Authors:  Wen Cheng; Xiufang Ren; Chuanbao Zhang; Jinquan Cai; Sheng Han; Anhua Wu
Journal:  Mol Neurobiol       Date:  2016-09-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.